Iovance Biotherapeutics (IOVA) Other Non-Current Assets (2011 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Other Non-Current Assets of $8.3 million for Q1 2026, up 1846.24% year-over-year from $426000.0 in Q1 2025, and up 38.65% quarter-over-quarter from $6.0 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Other Non-Current Assets for 12 consecutive years, with $8.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 1846.24% year-over-year to $8.3 million; the TTM figure through Mar 2026 stood at $8.3 million (up 1846.24% YoY), while the FY2025 annual figure was $6.0 million, down 5.96% from the prior year.
- Other Non-Current Assets grew to $8.3 million in Q1 2026 per IOVA's latest filing, from $6.0 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $66.4 million in Q2 2023 and bottomed at $189000.0 in Q4 2022.
- Historically, Other Non-Current Assets has averaged $9.0 million across 5 years, with a median of $6.4 million in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets tumbled 96.89% — and 2024, when it soared 2255.19%.
- Iovance Biotherapeutics' Other Non-Current Assets stood at $189000.0 in 2022, then jumped by 42.86% to $270000.0 in 2023, then jumped by 2255.19% to $6.4 million in 2024, then fell by 5.96% to $6.0 million in 2025, then soared by 38.65% to $8.3 million in 2026.
- Business Quant data shows IOVA's Other Non-Current Assets at $8.3 million in Q1 2026, $6.0 million in Q4 2025, and $9.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 6.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.43 Mn |
| Mar 31, 2026 | 8.29 Mn |
| Dec 31, 2025 | 5.98 Mn |
| Sep 30, 2025 | 9.27 Mn |
| Jun 30, 2025 | 5.94 Mn |
| Mar 31, 2025 | 426,000.00 |
| Dec 31, 2024 | 6.36 Mn |
| Mar 31, 2024 | 6.40 Mn |
| Dec 31, 2023 | 270,000.00 |
| Sep 30, 2023 | 282,000.00 |
| Jun 30, 2023 | 66.40 Mn |
| Mar 31, 2023 | 6.43 Mn |
| Dec 31, 2022 | 189,000.00 |
| Sep 30, 2022 | 6.43 Mn |
| Jun 30, 2022 | 6.43 Mn |
| Mar 31, 2022 | 6.08 Mn |
| Dec 31, 2021 | 6.08 Mn |
| Sep 30, 2021 | 6.08 Mn |
| Jun 30, 2021 | 6.08 Mn |
| Mar 31, 2021 | 6.08 Mn |